University of Pennsylvania

Fondazione Irccs Istituto Nazionale Dei Tumori

Other

Advanced Accelerator Applications Sa

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

Università Degli Studi Di Verona

Fondazione Irccs “instituto Nazionale Dei Tumori”

Colombatti, Marco

Silvana Canevari

Mariangela Figini

Daniel J Powell

George Coukos

Vito Di Cioccio

Franck Martin

Marco Colombatti

Giovanni Maurizi

Giulio Fracasso

Sara Cingarlini

Margherita Cattozzo

Di Cioccio Vito

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

Human alpha-folate receptor chimeric antigen receptor

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having &#x3b1;-folate receptor (FR&#x3b1;) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Compositions and methods for treating cancer

An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.

Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof

Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR&#x3b1;), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: &#x2014;RASESVSFLGINLIH (SEQ ID NO: 3), &#x2014;QASNKDT (SEQ ID NO: 4), &#x2014;LQSKNFPPYT (SEQ ID NO: 5), and wherein the constant region of said light chain is a kappa constant region.

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Growing community of inventors

Milan, Italy

Silvana Canevari